Influences of Angiotensin-neprilysin Inhibition With Sacubitril/Valsartan (ENTRESTO) on Centrally Generated Sympathetic Activity in Heart Failure Patients
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 16 Oct 2018
At a glance
- Drugs Sacubitril/valsartan (Primary) ; Valsartan
- Indications Heart failure
- Focus Pharmacodynamics
- Acronyms ARNI-Sy
- 05 Oct 2018 Status changed to withdrawn prior to enrolment, the reason provided is Difficulties in recruiting patients.
- 05 Oct 2018 Planned End Date changed from 31 Dec 2020 to 6 Sep 2018.
- 05 Oct 2018 Planned primary completion date changed from 31 Mar 2020 to 6 Sep 2018.